Literature DB >> 28875356

Response to "Commentary on: Undertreatment trend in elderly lung cancer patients in Brazil"-Jing-lan Tang, Chun-jie Hou.

Luiz Claudio Santos Thuler1, Guilherme Jorge Costa2, Maria Júlia Gonçalves de Mello3, Carlos Gil Ferreira4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28875356     DOI： 10.1007/s00432-017-2511-6

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  6 in total

1.  Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).

Authors:  Guilherme Jorge Costa; Ana Luisa Godoy Fernandes; José Rodrigues Pereira; J Randall Curtis; Ilka Lopes Santoro
Journal:  Lung Cancer       Date:  2006-06-06       Impact factor: 5.705

2.  Undertreatment trend in elderly lung cancer patients in Brazil.

Authors:  Guilherme Jorge Costa; Maria Júlia Gonçalves de Mello; Carlos Gil Ferreira; Luiz Claudio Santos Thuler
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-07       Impact factor: 4.553

3.  Commentary on: undertreatment trend in elderly lung cancer patients in Brazil.

Authors:  Jing-Lan Tang; Chun-Jie Hou
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-29       Impact factor: 4.553

4.  Limits of observational data in determining outcomes from cancer therapy.

Authors:  Sharon H Giordano; Yong-Fang Kuo; Zhigang Duan; Gabriel N Hortobagyi; Jean Freeman; James S Goodwin
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

5.  Prevalence of poor performance status in lung cancer patients: implications for research.

Authors:  Rogerio C Lilenbaum; John Cashy; Thomas A Hensing; Susan Young; David Cella
Journal:  J Thorac Oncol       Date:  2008-02       Impact factor: 15.609

Review 6.  The impact of comorbidity on cancer survival: a review.

Authors:  Mette Søgaard; Reimar Wernich Thomsen; Kristine Skovgaard Bossen; Henrik Toft Sørensen; Mette Nørgaard
Journal:  Clin Epidemiol       Date:  2013-11-01       Impact factor: 4.790
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.